Literature DB >> 2873839

Gly-Pro-Arg-Pro modifies the glutamine residues in the alpha- and gamma-chains of fibrinogen: inhibition of transglutaminase cross-linking.

K E Achyuthan, J V Dobson, C S Greenberg.   

Abstract

During blood clotting Factor XIIIa, a transglutaminase, catalyzes the formation of covalent bonds between the epsilon-amino group of lysine and the gamma-carboxamide group of peptide-bound glutamine residues between fibrin molecules. We report that glycyl-L-prolyl-L-arginyl-L-proline (GPRP), a tetrapeptide that binds to the fibrin polymerization sites (D-domain) in fibrin(ogen), inhibits transglutaminase cross-linking by modifying the glutamine residues in the alpha- and gamma-chains of fibrinogen. Purified platelet Factor XIIIa, and tissue transglutaminase from adult bovine aortic endothelial cells were used for the cross-linking studies. Gly-Pro (GP) and Gly-Pro-Gly-Gly (GPGG), peptides which do not bind to fibrinogen, had no effect on transglutaminase cross-linking. GPRP inhibited platelet Factor XIIIa-catalyzed cross-linking between the gamma-chains of the following fibrin(ogen) derivatives: fibrin monomers, fibrinogen and polymerized fibrin fibers. GPRP functioned as a reversible, noncompetitive inhibitor of Factor XIIIa-catalyzed incorporation of [3H]putrescine and [14C]methylamine into fibrinogen and Fragment D1. GPRP did not inhibit 125I-Factor XIIIa binding to polymerized fibrin, demonstrating that the Factor XIIIa binding sites on fibrin were not modified. GPRP also had no effect on Factor XIIIa cross-linking of [3H]putrescine to casein. This demonstrates that GPRP specifically modified the glutamine cross-linking sites in fibrinogen, and had no effect on either Factor XIIIa or the lysine residues in fibrinogen. GPRP also inhibited [14C]putrescine incorporation into the alpha- and gamma-chains of fibrinogen without inhibiting beta-chain incorporation, suggesting that the intermolecular cross-linking sites were selectively affected. Furthermore, GPRP inhibited tissue transglutaminase-catalyzed incorporation of [3H]putrescine into both fibrinogen and Fragment D1, without modifying [3H]putrescine incorporation into casein. GPRP also inhibited intermolecular alpha-alpha-chain cross-linking catalyzed by tissue transglutaminase. This demonstrates that the glutamine residues in the alpha-chains involved in intermolecular cross-linking are modified by GPRP. This is the first demonstration that a molecule binding to the fibrin polymerization sites on the D-domain of fibrinogen modifies the glutamine cross-linking sites on the alpha- and gamma-chains of fibrinogen.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873839     DOI: 10.1016/0167-4838(86)90279-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin.

Authors:  David J Schneider; Burton E Sobel
Journal:  J Thromb Thrombolysis       Date:  2008-07-08       Impact factor: 2.300

2.  Fibrin serves as a divalent ligand that regulates neutrophil-mediated melanoma cells adhesion to endothelium under shear conditions.

Authors:  Tugba Ozdemir; Pu Zhang; Changliang Fu; Cheng Dong
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-18       Impact factor: 4.249

3.  Effects on platelet function of a direct acting antagonist of coagulation factor Xa.

Authors:  Sukit M Ringwala; Peter M Dibattiste; David J Schneider
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

4.  Thrombin-induced conversion of fibrinogen to fibrin results in rapid platelet trapping which is not dependent on platelet activation or GPIb.

Authors:  Gavin E Jarvis; Ben T Atkinson; Jon Frampton; Steve P Watson
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

5.  Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release.

Authors:  Sybille Rex; Lea M Beaulieu; David H Perlman; Olga Vitseva; Price S Blair; Mark E McComb; Catherine E Costello; Jane E Freedman
Journal:  Thromb Haemost       Date:  2009-07       Impact factor: 5.249

6.  The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro.

Authors:  Friederike K Keating; David J Schneider
Journal:  J Thromb Thrombolysis       Date:  2008-06-25       Impact factor: 2.300

7.  Increased platelet expression of FcGammaRIIa and its potential impact on platelet reactivity in patients with end stage renal disease.

Authors:  Feliciano A Serrano; Mohamed El-Shahawy; Richard J Solomon; Burton E Sobel; David J Schneider
Journal:  Thromb J       Date:  2007-06-04

8.  Platelet collagen receptor Glycoprotein VI-dimer recognizes fibrinogen and fibrin through their D-domains, contributing to platelet adhesion and activation during thrombus formation.

Authors:  I Induruwa; M Moroi; A Bonna; J-D Malcor; J-M Howes; E A Warburton; R W Farndale; S M Jung
Journal:  J Thromb Haemost       Date:  2018-01-15       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.